Finding the optimal regimen for short-term daily recombinant human erythropoietin treatment for blood-saving purpose in patients undergoing unilateral primary total hip arthroplasty: a double-blinded randomized placebo-controlled trial

Table 1 Baseline demographic and clinical characteristics

Variable	Group A (n = 60)	Group B (n = 60)	Group C (n = 60)	P Value
Demographic characteristic
Age	66.40 ± 9.82	63.21 ± 10.82	64.38 ± 9.14	0.2093
Female (no. [%] of patients)	39 (65.0%)	34 (56.7%)	36 (60.0%)	0.643
Height	1.60 ± 0.07	1.62 ± 0.06	1.61 ± 0.07	0.2636
Weight	64.12 ± 9.84	65.73 ± 10.15	66.31 ± 9.91	0.4611
BMI	26.11 ± 4.02	25.81 ± 3.87	26.52 ± 3.41	0.5868
Operated side (no. of patients)				0.420
Left	31	26	33
Right	29	34	27
Diagnosis (no. of patients)				0.849
ONFH	22	25	23
OA	38	35	37
ASA class (no. of patients)				0.734
I	11	13	12
II	43	40	41
III	6	7	7
Preoperative laboratory values
Hemoglobin (g/L)	120.7 ± 9.3	119.9 ± 10.4	122.4 ± 9.2	0.3509
Reticulocyte (× 10^12/L)	0.0676 ± 0.031	0.0714 ± 0.028	0.0663 ± 0.025	0.5929

BMI body mass index, ONFH osteonecrosis of femoral head, OA osteoarthritis ASA American Society of Anesthesiologists
The p value represents the result of one-way analysis of variance for independent means for continuous variables or the chi-square test for independent proportions among the 3 groups

ISSN: 1471-2474